Oculis Holding AG (OCS) Cash from Operations (2022 - 2026)
Oculis Holding AG (OCS) recorded quarterly Cash from Operations of 19585420.81 in Q1 2026, up 6.16% quarter-over-quarter from 20870763.3 in Q4 2025, and up 7.14% on a YoY basis from 18280015.07 in Q1 2025.
Oculis Holding AG (OCS) Cash from Operations (2022 - 2026) Analysis & Trends
Oculis Holding AG's Cash from Operations history runs 5 years deep, the most recent figure standing at 19585420.81 for Q1 2026.
- In Q1 2026, Cash from Operations rose 7.14% year-over-year to 19585420.81; the TTM figure through Mar 2026 stood at 78056596.89 (down 28.13% YoY), while the FY2025 annual figure was 82957561.87, down 48.56% from the prior year.
- Cash from Operations was 19585420.81 for Q1 2026 at Oculis Holding AG, up from 20870763.3 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 6781397.15 in Q4 2022 to a low of 21091606.91 in Q1 2025.
- Historically, Cash from Operations has averaged 15322007.63 across 5 years, with a median of 15718761.35 in 2024.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations sank 136.21% in 2023, then advanced 24.15% in 2024.
- A 5-year view of Cash from Operations shows it stood at 6781397.15 in 2022, then tumbled by 136.21% to 16018579.72 in 2023, then advanced by 24.15% to 12150358.55 in 2024, then slumped by 71.77% to 20870763.3 in 2025, then increased by 6.16% to 19585420.81 in 2026.
- The last three Cash from Operations figures came in at 19585420.81 (Q1 2026), 20870763.3 (Q4 2025), and 16773969.47 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -19.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.59 Mn |
| Mar 31, 2026 | -19.59 Mn |
| Dec 31, 2025 | -20.87 Mn |
| Dec 31, 2025 | -20.87 Mn |
| Sep 30, 2025 | -16.77 Mn |
| Sep 30, 2025 | -16.77 Mn |
| Jun 30, 2025 | -20.83 Mn |
| Jun 30, 2025 | -20.83 Mn |
| Mar 31, 2025 | -21.09 Mn |
| Mar 31, 2025 | -21.09 Mn |
| Dec 31, 2024 | -12.15 Mn |
| Dec 31, 2024 | -12.15 Mn |
| Sep 30, 2024 | -12.48 Mn |
| Sep 30, 2024 | -12.48 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Jun 30, 2024 | -15.19 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Mar 31, 2024 | -15.72 Mn |
| Dec 31, 2023 | -16.02 Mn |
| Dec 31, 2023 | -16.02 Mn |